Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Revance Therapeutics Inc RVNC

Healthcare
Revance Therapeutics, Inc. is a biotechnology company focused on developing and commercializing aesthetic and therapeutic offerings. The Company's portfolio includes DAXXIFY (DaxibotulinumtoxinA-lanm) for injection and the RHA Collection of dermal fillers in the United States. It has also partnered with Viatris to develop a biosimilar to onabotulinumtoxinA for injection and Fosun to... see more

Recent & Breaking News (NDAQ:RVNC)

Mid-Day Market Update: Barnes & Noble Education Surges After Q2 Results; Ascena Retail Shares Slide

Benzinga.com  December 5, 2017

Revance’s RT002 Meets Primary and All Secondary Endpoints, Achieves 6-Month Duration in Pivotal SAKURA Phase 3 Trials for Glabellar Lines

Business Wire December 5, 2017

Revance Plans Phase 3 Program for RT002 Injectable to Treat Cervical Dystonia

Business Wire November 29, 2017

Revance Announces Orphan Drug Designation of RT002 for the Treatment of Cervical Dystonia

Business Wire November 20, 2017

Revance Releases Third Quarter 2017 Results

Business Wire November 2, 2017

Revance Therapeutics, Inc. to Host Earnings Call

Accesswire November 2, 2017

Revance Therapeutics to Release Third Quarter 2017 Financial Results Thursday, November 2, 2017

Business Wire October 18, 2017

Revance Completes Patient Enrollment in Phase 2 Program for RT002 Injectable in the Management of Plantar Fasciitis

Business Wire October 18, 2017

Revance to Participate in the Cantor Fitzgerald 2017 Global Healthcare Conference

Business Wire September 19, 2017

Revance Appoints Mark Foley to its Board of Directors

Business Wire September 6, 2017

Revance to Participate in the 2017 Wells Fargo Securities Healthcare Conference

Business Wire August 30, 2017

Revance Releases Second Quarter 2017 Results

Business Wire August 3, 2017

Revance Therapeutics Expands Leadership Team, Appointing Todd Zavodnick Chief Commercial Officer and President, Aesthetics & Therapeutics

Business Wire August 1, 2017

Revance Therapeutics to Release Second Quarter 2017 Financial Results Thursday, August 3, 2017

Business Wire July 24, 2017

Positive BELMONT Phase 2 Trial Results Published in Dermatologic Surgery

Business Wire June 15, 2017

Revance Reports Additional Positive Week 24 Efficacy Results from RT002 Injectable Phase 2 Cervical Dystonia Trial

Business Wire June 5, 2017

Revance to Participate in Upcoming Investor Conferences

Business Wire June 1, 2017

Revance Announces Positive Top-Line 24-Week Duration of Effect Results in All Three Cohorts in RT002 Injectable Phase 2 Cervical Dystonia Trial

Business Wire May 18, 2017

Revance Releases First Quarter 2017 Results

Business Wire May 9, 2017

Investor Network: Revance Therapeutics, Inc. to Host Earnings Call

Accesswire May 9, 2017